12:00 AM
Nov 17, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Volociximab: Phase I started

Ophthotech began a multiple ascending-dose Phase I trial of intravitreous volociximab with or without 0.5 mg/eye of Lucentis ranibizumab from Genentech Inc. (NYSE:DNA, South San...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >